ArticleMolecular pharmacology2016
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells.
Open access · bronzeAbstract read
In one paragraph
Article in Molecular pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 102 papers.
0numbers the graph read from it
0cells of the map it votes in
102citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
102 citing papers in PubMed, 157 citations in OpenAlex.
- Cooperation or Conflict? Molecular and Physiological Cross-Talk Between the Aryl Hydrocarbon and Vitamin D Receptors.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Live Biotherapeutic Products (LBPs) as Promising Microbiome-Based Medicines for Colorectal Cancer (CRC): Mechanistic Basis, Therapeutic Applications, and Translational Challenges.Probiotics and antimicrobial proteins · 2026Review
- SLC7A5 promotes colorectal cancer liver metastasis by reprogramming tryptophan metabolism through the Kyn/XANA‒AhR axis and reshaping the immune microenvironment.Clinical and translational medicine · 2026Article
- Targeting tryptophan metabolism in breast cancer immunotherapy: Recent advances and future prospects.Translational oncology · 2026Review
- Relationship Between Gut Microbiota and Cancer Neuro-Immunity.Microbial biotechnology · 2026Review
- Clinical efficacy and multi-omics analysis of Si-Ni-San for depression treatment in breast cancer patients: a randomized, double-blind, placebo-controlled, crossover trial.Chinese medicine · 2026Article
- An anoikis-based risk model predicts outcomes and is associated with the immune microenvironment in adrenocortical carcinoma.Frontiers in molecular biosciences · 2026Article
- A Review of Aryl Hydrocarbon Receptor-Mediated Immune Regulation in Cutaneous Squamous Cell Carcinoma Progression.ImmunoTargets and therapy · 2026Review
- A positive feedback loop of kynurenine-AhR-EMT upregulates tryptophan metabolic enzymes via epigenetic modification to facilitate immune escape in triple-negative breast cancer.Molecular & cellular oncology · 2026Article
- Depletion of tryptophanyl-tRNA synthetase and tryptophan accumulation triggers p53-dependent apoptosis.Cell death discovery · 2025Article
- Network toxicology and multiomics reveal bisphenol A-mediated immune evasion in breast cancer.The Journal of international medical research · 2025Article
- The aryl hydrocarbon receptor: a rehabilitated target for therapeutic immune modulation.Nature reviews. Drug discovery · 2025Review
- Amino acid metabolism in breast cancer: pathogenic drivers and therapeutic opportunities.Protein & cell · 2025Review
- Protein-Level Analysis of Differential Response to Chemotherapy in Triple-Negative Breast Cancer Identifies CYP1B1 as a Biomarker for Chemotherapy Resistance.Cancer research communications · 2025Article
- Article
- Gut Microbial Tryptophan Metabolism Is Involved in Post-Cardiac Arrest Brain Injury via Pyroptosis Modulation.CNS neuroscience & therapeutics · 2025Article
- Diverse Physiological Roles of Kynurenine Pathway Metabolites: Updated Implications for Health and Disease.Metabolites · 2025Review
- The aryl hydrocarbon receptor controls IFN-γ-induced immune checkpoints PD-L1 and IDO via the JAK/STAT pathway in lung adenocarcinoma.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- The Complex World of Kynurenic Acid: Reflections on Biological Issues and Therapeutic Strategy.International journal of molecular sciences · 2024Review
- The Aryl Hydrocarbon Receptor Controls IFNγ-Induced Immune Checkpoints PD-L1 and IDO via the JAK/STAT Pathway in Lung Adenocarcinoma.bioRxiv : the preprint server for biology · 2024Article
42 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Olga NovikovDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Zhongyan WangDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Elizabeth A StanfordDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Ashley J ParksDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Alejandra Ramirez-CardenasDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Esther LandesmanDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Israa LakloukDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Carmen Sarita-ReyesDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Daniel GusenleitnerDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Amy LiDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Stefano MontiDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Sara ManteigaDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
Kyongbum LeeDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.).
David H SherrDepartment of Environmental Health, Boston University School of Public Health, Boston, Massachusetts (O.N., Z.W., E.A.S., A.J.P., A.R.-C., D.H.S.); Boston University Molecular and Translational Medicine Program, Boston, Massachusetts (O.N., E.A.S.); Department of Medicine, Division of Computational Biomedicine, Boston University School of Medicine, Boston, Massachusetts (D.G., A.L., S.Mo.); Department of Pathology and Laboratory Medicine, Boston University School of Medicine, Boston, Massachusetts (E.L., I.L., C.S.-R.); and Department of Chemical and Biological Engineering, Tufts University, Medford, Massachusetts (S.Ma., K.L.) dsherr@bu.edu.
Tufts University · USBoston University · US
Funding
Training CoreP42ES007381 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI HAHN, MARK E · 1995 to 2019
$46.1MNIEHS NIH HHS P42 ES007381
Abstract
The endogenous ligand-activated aryl hydrocarbon receptor (AHR) plays an important role in numerous biologic processes. As the known number of AHR-mediated processes grows, so too does the importance of determining what endogenous AHR ligands are produced, how their production is regulated, and what biologic consequences ensue. Consequently, our studies were designed primarily to determine whether ER
Indexed as
Cell MovementGene AmplificationCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansImmunohistochemistryKynurenineLigandsModels, BiologicalReceptors, Aryl HydrocarbonReceptors, EstrogenReceptors, ProgesteroneRNA, MessengerERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesKynurenineLigandsReceptors, Aryl HydrocarbonReceptors, EstrogenReceptors, ProgesteroneRNA, MessengerTryptophanTryptophan OxygenaseXanthurenatesxanthurenic acid
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.